XNAS · RGEN
-0.73% · -$1.30 · Vol 1.4M
Market closed · last close 4:00 PM ET · price as of 16:28:32 ET
Repligen Corp

Repligen Corp

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$176.89
Card
Relationship Map

Follow $RGEN

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $RGEN by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Analyst data unavailable at compute time
RGEN
Repligen Corp
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

57/ 100
Veridion Score
Middle range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: MEDIUM · 5 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is RGEN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading RGEN catalysts
About Repligen Corp
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
1986
Employees
2K
Country
US

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$179.10
Day high
$179.10
Day low
$176.29
Previous close
$178.19
52W high
$182.03
-2.83% from high
52W low
$102.87
94% of range
Market cap
$10.1B
P/E
232.75×
EPS
$0.7600
Beta
0.41
Shares out
56.4M
Volume
1.4M
1.41× rel vol
Avg volume
965K
VWAP
$177.40
Price history computed in-house
1W
+7.09%
1M
-1.89%
3M
+33.99%
1Y
+44.63%
YTD
+7.95%
SMA 50 $161.03 · above
SMA 200 $142.28 · above
52W position 94%

RGEN overview

Loading financial statements
Loading RGEN Form 4 filings
Public disclosures

Congress activity in RGEN

No receipt-qualified Congressional disclosure is present for RGEN in the cached public ledger.

Federal contracts

RGEN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RGEN in this window.
Lobbying spend

RGEN lobbying filings, year to date.

Registered lobbying filings matched to Repligen Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RGEN in this window.
Loading news for RGEN
Analyst ratings
Sovereign unlock shows live analyst consensus for RGEN.
Options
Sovereign unlock shows live options positioning for RGEN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.